ABBV vs ACGL Stock Comparison

Scores Breakdown

Metric	ABBV	ACGL
📈 Growth	26/30	16/30
💰 Profitability	18/20	17/20
🏦 Financial Health	6/20	18/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	8/10	4/10
Overall Score	64/100	71/100

Side-by-Side Summaries

ABBV Analysis	ACGL Analysis
📈 Growth & Financial Trajectory Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2). 💰 Margins & Cash Flow Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters. 🛡️ Balance Sheet & Liquidity Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations. ⚠️ Key Drivers & Risks Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power. Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.	📈 Growth & Financial Trajectory From 2024 Q3 to 2026 Q2, Revenues remained in a tight band around $4.47–$5.21B, finishing at $4.67B in 2026 Q2 (slightly below the start). The eight-quarter path shows a trough in 2025 Q3 (~~$4.51B) and a peak in 2025 Q2 (~~$5.21B), signaling modest top-line volatility rather than sustained growth. Conversely, Net Income Attributable To Parent rose from about $886M in 2024 Q3 to $1.057B in 2026 Q2, reflecting improving profitability despite revenue fluctuations. Net income growth (~+19%) over the period supports a cautious positive trajectory. 💰 Margins & Cash Flow Operating margins have been solid, frequently in the mid-20s to low-30s range (examples: 2025 Q1 ~30%, 2025 Q3 ~34%, 2024 Q4 ~14–21% depending on quarter’s mix). This indicates healthy operating leverage when revenue spikes occur. Cash flow shows robust operating activity: Net Cash Flow From Operating Activities generally around $1.1–$2.2B per quarter (e.g., 2026 Q2 ~$1.32B, 2025 Q4 ~$2.19B). Investing activities are routinely negative, with ongoing cash used for growth, while financing activity varies by quarter. Overall, cash generation supports ongoing liquidity and shareholder value. 🛡️ Balance Sheet & Liquidity Balance sheets exhibit solid liquidity and limited noncurrent leverage. Across quarters, current assets exceed current liabilities (e.g., 2026 Q2: $85.18B vs. $61.15B current liabilities), yielding a healthy current ratio (~1.4). Noncurrent liabilities are effectively zero, and equity attributable to parent sits around $24.0–$24.2B, implying durable solvency and resilience against near-term shocks. ⚠️ Key Drivers & Risks Drivers: Insurance underwriting performance, pricing discipline, and favorable catastrophe experience can sustain margins and earnings; strong capital markets support reinsurance activities. Risks: Catastrophe losses, regulatory changes, and revenue cyclicality can pressure margins and cash flows; valuation sensitivity to premiums/rates and reserve development.

ABBV Analysis

ACGL Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

From 2024 Q3 to 2026 Q2, Revenues remained in a tight band around $4.47–$5.21B, finishing at $4.67B in 2026 Q2 (slightly below the start). The eight-quarter path shows a trough in 2025 Q3 (~~$4.51B) and a peak in 2025 Q2 (~~$5.21B), signaling modest top-line volatility rather than sustained growth. Conversely, Net Income Attributable To Parent rose from about $886M in 2024 Q3 to $1.057B in 2026 Q2, reflecting improving profitability despite revenue fluctuations. Net income growth (~+19%) over the period supports a cautious positive trajectory.

💰 Margins & Cash Flow

Operating margins have been solid, frequently in the mid-20s to low-30s range (examples: 2025 Q1 ~30%, 2025 Q3 ~34%, 2024 Q4 ~14–21% depending on quarter’s mix). This indicates healthy operating leverage when revenue spikes occur. Cash flow shows robust operating activity: Net Cash Flow From Operating Activities generally around $1.1–$2.2B per quarter (e.g., 2026 Q2 ~$1.32B, 2025 Q4 ~$2.19B). Investing activities are routinely negative, with ongoing cash used for growth, while financing activity varies by quarter. Overall, cash generation supports ongoing liquidity and shareholder value.

🛡️ Balance Sheet & Liquidity

Balance sheets exhibit solid liquidity and limited noncurrent leverage. Across quarters, current assets exceed current liabilities (e.g., 2026 Q2: $85.18B vs. $61.15B current liabilities), yielding a healthy current ratio (~1.4). Noncurrent liabilities are effectively zero, and equity attributable to parent sits around $24.0–$24.2B, implying durable solvency and resilience against near-term shocks.

⚠️ Key Drivers & Risks

Drivers: Insurance underwriting performance, pricing discipline, and favorable catastrophe experience can sustain margins and earnings; strong capital markets support reinsurance activities.
Risks: Catastrophe losses, regulatory changes, and revenue cyclicality can pressure margins and cash flows; valuation sensitivity to premiums/rates and reserve development.

Similar Companies

ABT Score: 71 AMGN Score: 67 BMY Score: 72 GILD Score: 46 JNJ Score: 86 LLY Score: 82 MRK Score: 58 MRNA Score: 38 PFE Score: 55

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"